Compare TYRA & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
Current Price
| Metric | TYRA | IRS |
|---|---|---|
| Founded | 2018 | 1943 |
| Country | United States | Argentina |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2021 | 1998 |
| Metric | TYRA | IRS |
|---|---|---|
| Price | $19.70 | $11.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 3 |
| Target Price | ★ $47.45 | $21.87 |
| AVG Volume (30 Days) | ★ 577.7K | 256.7K |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 12.46% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.14 |
| P/E Ratio | ★ N/A | $3.66 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.94 | $11.82 |
| 52 Week High | $40.65 | $19.14 |
| Indicator | TYRA | IRS |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 32.92 |
| Support Level | $18.46 | N/A |
| Resistance Level | $22.69 | $16.10 |
| Average True Range (ATR) | 1.19 | 0.62 |
| MACD | -0.10 | -0.12 |
| Stochastic Oscillator | 12.33 | 8.84 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segments include Shopping Malls, which comprise lease and service revenues principally related to the rental of commercial and other spaces in the company's shopping malls; Offices, which include lease revenues and other service revenues related to office activities; Sales and Developments, which include the development, maintenance, and sales of undeveloped parcels of land and/or trading properties; Hotels, which mainly include revenues from rooms, catering, and restaurants; and others. The company generates the majority of its revenue from the Shopping Malls segment.